Colorectal Cancer Clinical Trials in Austin

Showing 61-80 of 136 trials

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

NCT06620627

The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

Colorectal Cancer Screening

Natera, Inc.5,000 participantsStarted Jan 2024

Austin, Texas, United States

COMPLETEDNA< 1 mile

Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

NCT04739722

This study was a prospective analysis conducted by Geneoscopy Inc. to evaluate the ColoSense test, which is a multi-target stool RNA test for colorectal cancer screening.

Colorectal CancerAdvanced AdenocarcinomaSerrated Polyp

Geneoscopy, Inc.14,263 participantsStarted Apr 2021

St Louis, Missouri, United States • Austin, Texas, United States

COMPLETEDPHASE1< 1 mile

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

NCT03819387

This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).

Non-Small Cell Lung CancerPancreatic CancerColorectal Cancer

Nitto BioPharma, Inc.49 participantsStarted Mar 2019

Beverly Hills, California, United States • La Jolla, California, United States • Tampa, Florida, United States +6 more locations

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Colorectal Cancer Trials in Other Cities

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Diffusion-Weighted MRI for Liver Metastasis

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Other Conditions in Austin